Lerma v. Schiff Nutrition International, Inc.

  1. March 27, 2015

    Glucosamine Class Can't Back Out Of $5M Deal, Judge Says

    A California magistrate refused Thursday to allow plaintiffs suing Schiff Nutrition International Inc. for allegedly deceptively marketing its glucosamine supplement as an arthritis treatment to back out of their proposed $5 million deal, saying "possible" objections and a recent Seventh Circuit decision don't justify their request.

  2. February 24, 2015

    Schiff Says Glucosamine Class Can't Flake On $5M Deal

    Schiff Nutrition International Inc. on Monday urged a California federal judge not to let plaintiffs back out on a $5 million class settlement over claims that it falsely marketed a glucosamine dietary supplement as an arthritis treatment, arguing that the Seventh Circuit's criticism of a different settlement over a similar product doesn't apply to this case. 

  3. February 03, 2015

    Schiff Nutrition Foes Can't Halt $5M Pact's Approval Process

    A California federal magistrate on Monday nixed a request by plaintiffs to stay the approval process for a $5 million settlement in a class action accusing Schiff Nutrition International Inc. of falsely marketing its flagship dietary supplement as an arthritis treatment, saying a Seventh Circuit decision to overturn a different settlement didn't affect this case.

  4. March 26, 2014

    Schiff Nutrition Pays $5M In Dietary Supplement Labeling Row

    Schiff Nutrition International Inc. has agreed to pay at least $5 million to settle a proposed class action accusing the company of falsely marketing its flagship dietary supplement as an arthritis treatment, according to a Tuesday filing in California federal court.

  5. May 17, 2011

    Schiff Nutrition Sued Over Dietary Supplement Claims

    A California consumer hit Schiff Nutrition International Inc. with a class action Friday, accusing the company of falsely marketing its flagship dietary supplement as an arthritis treatment despite lacking any scientific evidence supporting its claims.